text_1: Increased LDL receptors plays a role in the reduction of plasma Lp(a).
text_2: Alirocumab had no effects on FCRs or PRs of very low-density lipoproteins-apoB and very low-density lipoproteins triglycerides or on postprandial plasma triglycerides or apoB48 concentrations.